A dose response evaluation of delta-1-testololactone in advanced breast cancer.

Suppr

超能文献

作者信息

Volk H, Deupree R H, Goldenberg I S, Wilde R C, Carabasi R A, Escher G C

出版信息

Cancer. 1974 Jan;33(1):9-13. doi: 10.1002/1097-0142(197401)33:1<9::aid-cncr2820330104>3.0.co;2-#.

DOI:10.1002/1097-0142(197401)33:1<9::aid-cncr2820330104>3.0.co;2-#

PMID:4129562

Abstract

摘要

相似文献

A dose response evaluation of delta-1-testololactone in advanced breast cancer.

Cancer. 1974 Jan;33(1):9-13. doi: 10.1002/1097-0142(197401)33:1<9::aid-cncr2820330104>3.0.co;2-#.

Androgenic therapy for advanced breast cancer in women. A report of the cooperative breast cancer group.

JAMA. 1973 Mar 12;223(11):1267-8.

Combined high-dose delta1-testololactone with low-dose 5-fluorouracil in the treatment of metastatic breast cancer.

Oncology. 1973;27(6):493-501. doi: 10.1159/000224759.

delta 1-testololactone: clinical trials'.

Cancer Res. 1982 Aug;42(8 Suppl):3387s-3388s.

Palliative treatment of mammary cancer. Response of soft tissue, pleural and pulmonary disease.

Arch Surg. 1973 Jul;107(1):43-8. doi: 10.1001/archsurg.1973.01350190033010.

Teslac.

Med Lett Drugs Ther. 1970 May 29;12(11):45-6.

Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group.

Cancer. 1975 Aug;36(2):308-10. doi: 10.1002/1097-0142(197508)36:2<308::aid-cncr2820360203>3.0.co;2-1.

Clinical trial of delta-1-testololactone (NSC 23759), medroxy progesterone acetate (NSC 26386) and oxylone acetate (NSC 47438) in advanced female mammary cancer. A report of the cooperative breast cancer group.

Cancer. 1969 Jan;23(1):109-12. doi: 10.1002/1097-0142(196901)23:1<109::aid-cncr2820230112>3.0.co;2-1.

Hormonal therapy of breast cancer.

Cancer. 1972 Dec;30(6):1541-2. doi: 10.1002/1097-0142(197212)30:6<1541::aid-cncr2820300620>3.0.co;2-3.

Does thyroid substance improve response of breast cancer to surgical castration.

Cancer. 1974 Apr;33(4):1082-5. doi: 10.1002/1097-0142(197404)33:4<1082::aid-cncr2820330428>3.0.co;2-9.

引用本文的文献

Aromatase inhibitors and inactivators for breast cancer therapy.

Drugs Aging. 2002;19(4):277-98. doi: 10.2165/00002512-200219040-00003.

First generation aromatase inhibitors--aminoglutethimide and testololactone.

Breast Cancer Res Treat. 1994;30(1):57-80. doi: 10.1007/BF00682741.

Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.

Clin Pharmacokinet. 1987 Dec;13(6):393-406. doi: 10.2165/00003088-198713060-00004.

Anti-estrogens and aromatase inhibitors: tamoxifen and testolactone.

J Endocrinol Invest. 1988 Nov;11(10):755-62. doi: 10.1007/BF03350940.

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Drugs. 1988 Jun;35(6):685-710. doi: 10.2165/00003495-198835060-00005.

Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Cancer Chemother Pharmacol. 1990;26(4):241-4. doi: 10.1007/BF02897223.

Aromatase inhibitors in malignant diseases of aging.

Drugs Aging. 1992 Nov-Dec;2(6):530-45. doi: 10.2165/00002512-199202060-00008.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验